CardioNet Launches Enhanced Reporting Package for the Treatment of Atrial Fibrillation
October 01 2008 - 4:49PM
Business Wire
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical
technology company with an initial focus on the diagnosis and
monitoring of cardiac arrhythmias, today announced the release of
its new atrial fibrillation (AF) reporting package to enhance its
current AF Management Program. The CardioNet AF Management Program
offers a robust and comprehensive tool to the physician for the
diagnosis, treatment and management of their AF patients. The
program additionally provides physicians with an efficient and
flexible monitoring program to evaluate the clinical efficacy of
catheter and surgical ablation procedures allowing improved
management of these post surgical patients. CardioNet President and
CEO, Arie Cohen, said of the new reporting package, �Our goal to
continually provide physicians and patients with state of the art
capabilities is evident in today�s announcement, and we expect that
our products and services will continue to improve patient lives
and drive physician adoption of the CardioNet System.� The
reporting enhancements will strengthen CardioNet�s current
proprietary correlated Heart Rate Trend Chart and AF Burden Graph
by providing detailed atrial fibrillation statistics, including the
duration of AF episodes, the percentage of time that a patient is
in AF over a twenty four hour period, and heart rate trends while
the patient is in AF. Dr. Peter R. Kowey, CardioNet Medical
Director and Chief, Division of Cardiovascular Diseases at the Main
Line Health System, said, �Quantifying the amount of AF over time
represents a very important advance in caring for patients with
this common arrhythmia.� The CardioNet System is widely utilized by
physicians and is proven to be nearly three times superior at
detecting clinically significant atrial fibrillation1, a condition
which affects 2.2 million people in the United States. About
CardioNet CardioNet is the leading provider of ambulatory,
continuous, real-time outpatient management solutions for
monitoring relevant and timely clinical information regarding an
individual's health. CardioNet's initial efforts are focused on the
diagnosis and monitoring of cardiac arrhythmias, or heart rhythm
disorders, with a solution that it markets as the CardioNet System.
More information can be found at http://www.cardionet.com. 1
Journal of Cardiovascular Electrophysiology (Vol. 18, No. 2, March
2007). Forward Looking Statements This press release includes
certain forward-looking statements within the meaning of the �Safe
Harbor� provisions of the Private Securities Litigation Reform Act
of 1995 regarding, among other things, our ability to continue to
increase physician adoption and the positive impact of our AF
reporting on that process. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including important factors that could delay,
divert, or change any of them, and could cause actual outcomes and
results to differ materially from current expectations. These
factors include, among other things, the success of our sales and
marketing initiatives, market factors, internal research and
development initiatives, partnered research and development
initiatives, competitive product development and marketing, changes
in governmental regulations and legislation, the continued
consolidation of payors, acceptance of our new products and
services, patent protection and litigation. For further details and
a discussion of these and other risks and uncertainties, please see
our public filings with the Securities and Exchange Commission,
including our Annual Report and Quarterly Reports on Form 10-Q. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024